Trending...
- Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
- Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
- UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
BETHLEHEM, Pa.--(BUSINESS WIRE)--Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries. This IP, along with the current Saladax IP, covers the major antipsychotic drugs that are prescribed worldwide and places Saladax in a premier position in the antipsychotic drug testing field.
With this IP portfolio, Saladax has developed tests for chemistry analyzers commonly found in hospitals and a point-of-care instrument that can be used where centralized testing is not possible. These tests address a significant unmet clinical need for patients with serious mental illness (SMI) by providing rapid, actionable results to health care professionals (HCP). International and U.S. clinical guidelines have recently been established recommending antipsychotic drug testing. The availability of these tools will greatly enhance the ability of health care professionals to better manage their patients in real time.
SMI is a significant public health concern. The estimated economic impact of SMI worldwide is more than $2.5 trillion each year with the number of people that SMI affects growing rapidly. In the U.S. current data shows that more than 13 million adults in the U.S. experienced SMI in the past year. That is more than 3% of the adult population.1
More on The PennZone
Saladax is well positioned as the leading diagnostic company in the field of antipsychotic drug testing with a full panel of antipsychotic tests already on the market and a solid pipeline of new products.
"This is a very exciting time for Saladax and the field of therapeutic drug monitoring (TDM)." stated Sal Salamone, Founder and CEO of Saladax. "The availability of antipsychotic testing is arguably the most significant step in the field of TDM since the launch of the Abbott Diagnostics TDx platform back in the 1980's."
About Saladax Biomedical, Inc.
Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax's proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians in monitoring and optimizing patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit MyCareTests.com.
Contacts
More on The PennZone
Saladax Biomedical, Inc.
Salvatore Salamone
ssalamone@saladax.com
With this IP portfolio, Saladax has developed tests for chemistry analyzers commonly found in hospitals and a point-of-care instrument that can be used where centralized testing is not possible. These tests address a significant unmet clinical need for patients with serious mental illness (SMI) by providing rapid, actionable results to health care professionals (HCP). International and U.S. clinical guidelines have recently been established recommending antipsychotic drug testing. The availability of these tools will greatly enhance the ability of health care professionals to better manage their patients in real time.
SMI is a significant public health concern. The estimated economic impact of SMI worldwide is more than $2.5 trillion each year with the number of people that SMI affects growing rapidly. In the U.S. current data shows that more than 13 million adults in the U.S. experienced SMI in the past year. That is more than 3% of the adult population.1
More on The PennZone
- Prolific Press Opens Full-Length Book Submissions for Poetry, Fiction and Non-Fiction
- Clear Path Landscaping Announces Commercial and Residential Snow Removal for 2026-27 Season
- Montana Artist Ryan Jolley Receives Goodman Award at Mountain Oyster Club Art Show
- Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
- Scott Glickson Joins STS Capital Partners as Managing Director
Saladax is well positioned as the leading diagnostic company in the field of antipsychotic drug testing with a full panel of antipsychotic tests already on the market and a solid pipeline of new products.
"This is a very exciting time for Saladax and the field of therapeutic drug monitoring (TDM)." stated Sal Salamone, Founder and CEO of Saladax. "The availability of antipsychotic testing is arguably the most significant step in the field of TDM since the launch of the Abbott Diagnostics TDx platform back in the 1980's."
About Saladax Biomedical, Inc.
Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax's proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians in monitoring and optimizing patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit MyCareTests.com.
- Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
- Bessonova L, Ogden K, The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature review 2011. doi: 10.2147/CEOR.S259338
Contacts
More on The PennZone
- BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
- PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence
- 33,714 US social services nonprofits and the funding calls still open to them
- Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
Saladax Biomedical, Inc.
Salvatore Salamone
ssalamone@saladax.com
Filed Under: Business
0 Comments
Latest on The PennZone
- Inaugural 12 Trees of Christmas gala raises $525,000 for DMG research and family support
- BitTitan Expands MigrationWiz with SharePoint Sites Migration and Simplified Collaboration Licensing
- Olympic champion Katie Moon to compete at Pole Vault in Paradise in Key West
- Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
- Angela's Boutique Highlights Self-Care Gifts for Philadelphia Holiday Shoppers
- Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
- UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
- Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
- Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
- Veteran Antiques Expert John Swahn Releases New Book: The Truth About Antiques
- Steven Weisz of Art Imagined Photography to exhibit at ExpoMetro Florence, Italy
- Hope Survives Managing Director Jasmine Balignasay-Chavez Receives 2026 Catalyst Award
- LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
- Security Planning Tips For Your Holiday Event From Access Patrol Services
- Kellyn Co-Founder Meagan Grega Named President-Elect of the American College of Lifestyle Medicine
- Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award